Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Vet Ophthalmol. 2011 Apr 18;14(5):304–312. doi: 10.1111/j.1463-5224.2011.00877.x

Figure 1.

Figure 1

Dose-dependent treatment of mitomycin C (MMC) in canine stromal fibroblast (CSF) primary cultures. Bright-field images of CSF cultures were taken using a light microscope. (a) Untreated control and (b) 0.002% MMC demonstrated no change in cellular morphology. A single 2 min dose of 0.02% MMC (c) did not alter cellular morphology. Higher doses of MMC (0.04%, d) reduced CSF populations considerably without altering phenotype or viability. The anti-fibrotic effects of MMC at low dose and short exposure times are likely due to proliferation or growth inhibition.